S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Copper More Critical than Lithium? (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Copper More Critical than Lithium? (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Copper More Critical than Lithium? (Ad)
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Economic and National Security Threats Create Lithium Bonanza (Ad)
'The Sacrifice Zone': Myanmar bears cost of green energy
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Copper More Critical than Lithium? (Ad)
NASDAQ:INMB

INmune Bio - INMB Stock Forecast, Price & News

$9.30
-0.86 (-8.46%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.12
$10.10
50-Day Range
$6.59
$10.44
52-Week Range
$4.63
$30.37
Volume
57,811 shs
Average Volume
130,594 shs
Market Capitalization
$166.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.33

INmune Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
54.1% Upside
$14.33 Price Target
Short Interest
Healthy
8.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of INmune Bio in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$88,662 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.05) to ($1.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

343rd out of 1,098 stocks

Biological Products, Except Diagnostic Industry

56th out of 174 stocks

INMB stock logo

About INmune Bio (NASDAQ:INMB) Stock

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio Price Performance

NASDAQ:INMB traded down $0.86 during trading hours on Tuesday, hitting $9.30. The company's stock had a trading volume of 57,811 shares, compared to its average volume of 130,594. The business's 50-day moving average is $8.69 and its two-hundred day moving average is $8.39. The company has a market capitalization of $166.90 million, a PE ratio of -4.97 and a beta of 1.92. The company has a debt-to-equity ratio of 0.21, a quick ratio of 30.87 and a current ratio of 30.87. INmune Bio has a 52-week low of $4.63 and a 52-week high of $30.37.

INmune Bio (NASDAQ:INMB - Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.12. INmune Bio had a negative return on equity of 41.87% and a negative net margin of 9,233.15%. During the same period in the previous year, the business earned ($0.44) earnings per share. As a group, research analysts anticipate that INmune Bio will post -2.05 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. B. Riley downgraded INmune Bio from a "buy" rating to a "neutral" rating and dropped their target price for the company from $14.00 to $7.00 in a research report on Tuesday, May 24th. Maxim Group began coverage on INmune Bio in a report on Friday, May 6th. They issued a "buy" rating and a $22.00 price target for the company. Finally, BTIG Research reduced their price objective on INmune Bio from $31.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, May 24th.

Insider Buying and Selling at INmune Bio

In other news, CFO David J. Moss bought 7,700 shares of the stock in a transaction on Thursday, May 26th. The shares were bought at an average price of $6.27 per share, with a total value of $48,279.00. Following the completion of the acquisition, the chief financial officer now owns 1,244,651 shares of the company's stock, valued at $7,803,961.77. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Raymond Joseph Tesi acquired 6,300 shares of the firm's stock in a transaction that occurred on Thursday, May 26th. The shares were acquired at an average price of $6.41 per share, with a total value of $40,383.00. Following the completion of the purchase, the chief executive officer now directly owns 1,520,698 shares in the company, valued at $9,747,674.18. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CFO David J. Moss acquired 7,700 shares of the firm's stock in a transaction that occurred on Thursday, May 26th. The shares were bought at an average cost of $6.27 per share, for a total transaction of $48,279.00. Following the purchase, the chief financial officer now owns 1,244,651 shares of the company's stock, valued at $7,803,961.77. The disclosure for this purchase can be found here. 34.20% of the stock is owned by corporate insiders.

Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

INMB Stock News Headlines

Mizner Park office space fills up
See More Headlines
Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

INMB Company Calendar

Last Earnings
8/03/2022
Today
8/10/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INMB
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.33
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+54.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-30,340,000.00
Net Margins
-9,233.15%
Pretax Margin
-9,233.15%

Debt

Sales & Book Value

Annual Sales
$180,000.00
Book Value
$4.50 per share

Miscellaneous

Free Float
11,808,000
Market Cap
$166.90 million
Optionable
Not Optionable
Beta
1.92














INMB Stock - Frequently Asked Questions

Should I buy or sell INmune Bio stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INMB shares.
View INMB analyst ratings
or view top-rated stocks.

What is INmune Bio's stock price forecast for 2022?

3 Wall Street analysts have issued 1 year price targets for INmune Bio's stock. Their INMB share price forecasts range from $7.00 to $22.00. On average, they predict the company's share price to reach $14.33 in the next twelve months. This suggests a possible upside of 54.1% from the stock's current price.
View analysts price targets for INMB
or view top-rated stocks among Wall Street analysts.

How has INmune Bio's stock price performed in 2022?

INmune Bio's stock was trading at $10.20 on January 1st, 2022. Since then, INMB stock has decreased by 8.8% and is now trading at $9.30.
View the best growth stocks for 2022 here
.

When is INmune Bio's next earnings date?

INmune Bio is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our INMB earnings forecast
.

How were INmune Bio's earnings last quarter?

INmune Bio, Inc. (NASDAQ:INMB) released its quarterly earnings data on Wednesday, August, 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.12. INmune Bio had a negative net margin of 9,233.15% and a negative trailing twelve-month return on equity of 41.87%. During the same quarter in the prior year, the company posted ($0.44) earnings per share.

What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX).

What is INmune Bio's stock symbol?

INmune Bio trades on the NASDAQ under the ticker symbol "INMB."

Who are INmune Bio's major shareholders?

INmune Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Janney Montgomery Scott LLC (1.18%), Westside Investment Management Inc. (0.17%), Fermata Advisors LLC (0.13%), Sepio Capital LP (0.12%) and Northwestern Mutual Wealth Management Co. (0.02%). Insiders that own company stock include David J Moss, Linda F Powers, Mark William Lowdell, Raymond Joseph Tesi, Scott Juda and Timothy J Schroeder.
View institutional ownership trends
.

How do I buy shares of INmune Bio?

Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is INmune Bio's stock price today?

One share of INMB stock can currently be purchased for approximately $9.30.

How much money does INmune Bio make?

INmune Bio (NASDAQ:INMB) has a market capitalization of $166.90 million and generates $180,000.00 in revenue each year. The company earns $-30,340,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.

How many employees does INmune Bio have?

INmune Bio employs 10 workers across the globe.

How can I contact INmune Bio?

INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The official website for the company is www.inmunebio.com. The company can be reached via phone at (858) 964-3720 or via email at james@haydenir.com.

This page (NASDAQ:INMB) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.